Literature DB >> 17141632

PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis.

Wei Zhang1, Daorong Feng, Yulin Li, Kaori Iida, Barbara McGrath, Douglas R Cavener.   

Abstract

Mutations in PERK (EIF2AK3) result in permanent neonatal diabetes as well as several other anomalies that underlie the human Wolcott-Rallison syndrome, and these anomalies are mirrored in Perk knockout mice. To identify the cause of diabetes in PERK-deficient mice, we generated a series of tissue- and cell-specific knockouts of the Perk gene and performed a developmental analysis of the progression to overt diabetes. We discovered that PERK is specifically required in the insulin-secreting beta cells during the fetal and early neonatal period as a prerequisite for postnatal glucose homeostasis. However, PERK expression in beta cells is not required at the adult stage to maintain beta cell functions and glucose homeostasis. We show that PERK-deficient mice exhibit severe defects in fetal/neonatal beta cell proliferation and differentiation, resulting in low beta cell mass, defects in proinsulin trafficking, and abrogation of insulin secretion that culminate in permanent neonatal diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17141632     DOI: 10.1016/j.cmet.2006.11.002

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  128 in total

Review 1.  Proinsulin misfolding and diabetes: mutant INS gene-induced diabetes of youth.

Authors:  Ming Liu; Israel Hodish; Leena Haataja; Roberto Lara-Lemus; Gautam Rajpal; Jordan Wright; Peter Arvan
Journal:  Trends Endocrinol Metab       Date:  2010-08-18       Impact factor: 12.015

2.  ATF6alpha induces XBP1-independent expansion of the endoplasmic reticulum.

Authors:  Hemamalini Bommiasamy; Sung Hoon Back; Paolo Fagone; Kyungho Lee; Sasha Meshinchi; Elizabeth Vink; Rungtawan Sriburi; Matthew Frank; Suzanne Jackowski; Randal J Kaufman; Joseph W Brewer
Journal:  J Cell Sci       Date:  2009-05-15       Impact factor: 5.285

Review 3.  Getting the message in protein synthesis. Keystone Symposium on Translational Regulatory Mechanisms.

Authors:  Mauro Costa-Mattioli; Michael Bidinosti; Thomas E Dever
Journal:  EMBO Rep       Date:  2008-08-29       Impact factor: 8.807

4.  Endoplasmic reticulum (ER) chaperone regulation and survival of cells compensating for deficiency in the ER stress response kinase, PERK.

Authors:  Yukihiro Yamaguchi; Dennis Larkin; Roberto Lara-Lemus; Jose Ramos-Castañeda; Ming Liu; Peter Arvan
Journal:  J Biol Chem       Date:  2008-04-21       Impact factor: 5.157

Review 5.  Oxidative stress, unfolded protein response, and apoptosis in developmental toxicity.

Authors:  Allison Kupsco; Daniel Schlenk
Journal:  Int Rev Cell Mol Biol       Date:  2015-03-11       Impact factor: 6.813

Review 6.  Unfolded protein response signaling and metabolic diseases.

Authors:  Jaemin Lee; Umut Ozcan
Journal:  J Biol Chem       Date:  2013-12-09       Impact factor: 5.157

7.  PERK-dependent regulation of lipogenesis during mouse mammary gland development and adipocyte differentiation.

Authors:  Ekaterina Bobrovnikova-Marjon; Georgia Hatzivassiliou; Christina Grigoriadou; Margarita Romero; Douglas R Cavener; Craig B Thompson; J Alan Diehl
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

8.  The unfolded protein response of B-lymphocytes: PERK-independent development of antibody-secreting cells.

Authors:  Jennifer N Gass; Hao-Yuan Jiang; Ronald C Wek; Joseph W Brewer
Journal:  Mol Immunol       Date:  2007-09-05       Impact factor: 4.407

Review 9.  The role of the unfolded protein response in diabetes mellitus.

Authors:  Takao Iwawaki; Daisuke Oikawa
Journal:  Semin Immunopathol       Date:  2013-03-26       Impact factor: 9.623

10.  PERK regulates the proliferation and development of insulin-secreting beta-cell tumors in the endocrine pancreas of mice.

Authors:  Sounak Gupta; Barbara McGrath; Douglas R Cavener
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.